MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the fourth and final report for our 2016 series covering new data presented in Chicago.
This OncoPoll™ focuses on melanoma, with a little merkel cell carcinoma included for good measure. As with the entire melanoma therapy area for the past few years, it focuses of the use of the checkpoint inhibitors and BRAF + MEK inhibitors for the treatment of BRAF V600E/K-mutant melanoma.
Our most recent research from a global panel of active melanoma treaters reveals:
• Melanoma treaters in all locations continue to see updates and expansions about the use of the checkpoint inhibitors as very important clinical developments. Focus now is beginning to change towards combinations and use as initial treatment lines
• Physicians also recognize the utility and importance of targeted therapy for BRAF-mutant melanoma, especially now that longer-term data is becoming available
• Even though combinations of BRAF + MEK inhibitors will remain the primary 1st line treatment choice for BRAF-mutant melanoma for more treaters than anything else, the use of checkpoint inhibitors in the front line will make strong inroads as the preferred option
Download your complimentary copy of our report MDoutlook June 2016 Oncopoll – Skin Cancers.
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!